跳至主要内容
临床试验/NCT04053478
NCT04053478
招募中
不适用

Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study

Samuel Lunenfeld Research Institute, Mount Sinai Hospital1 个研究点 分布在 1 个国家目标入组 144 人2019年7月8日

概览

阶段
不适用
干预措施
Phenylephrine
疾病 / 适应症
Hypotension
发起方
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
入组人数
144
试验地点
1
主要终点
Motility index
状态
招募中
最后更新
26天前

概览

简要总结

Hypotension is one of the most common adverse effects of spinal anesthesia for cesarean deliveries, affecting as many as 55-90% of mothers. Hypotension during cesarean deliveries can have detrimental effects on the mother and neonate. Various vasopressors, such as ephedrine, phenylephrine and more recently norepinephrine, have been used for the prevention and treatment of hypotension at cesarean deliveries.

Ephedrine was historically considered as the gold standard vasopressor for the management of hypotension during cesarean deliveries. This was based on studies in animal models that showed preserved uteroplacental circulation with ephedrine and not with phenylephrine. However, multiple studies in the past several decades have shown that phenylephrine compared with ephedrine results in a more favorable fetal acid-base status. Consequently, the use of phenylephrine for blood pressure management during cesarean deliveries increased. Recently, norepinephrine was introduced in the obstetrical practice for the management of hypotension at cesarean deliveries, due to its ability to maintain maternal cardiac output better than phenylephrine.

Studies have also investigated the use of vasopressin to limit hypotension during CD. There have been case reports of successful vasopressin usage to treat post-spinal hypotension after CD in patients with advanced idiopathic pulmonary arterial hypertension as well as severe mitral stenosis with pulmonary hypertension. Its effect was associated with hemodynamic stability without evidence of harm to the mother or child. However, much controversy still exists surrounding the choice of vasopressor in the obstetric population, in large part due to their varying efficacies, and maternal and fetal effects.

Vasopressors used for the treatment of hypotension during cesarean deliveries can have significant direct or indirect effects on the perfusion of uteroplacental and umbilical vessels. Reduction of uteroplacental perfusion and constriction of umbilical vessels can result in fetal acidosis, however, the mechanisms for these effects are unclear. The investigators hypothesize that ephedrine, phenylephrine and norepinephrine and vasopressin have variable effects on the contractility of pregnant myometrium and umbilical arteries due to their variable actions on adrenergic alpha (α) and beta (β) receptors, as well as vasopressin1 and vasopressin2 receptors located in these tissues.

详细描述

One of the major concerns addressed in the literature is the risk of fetal acidosis related to the use of vasopressors, which varies according to the type of drug used. Since severe fetal acidosis is associated with a two- and four-fold increase in neonatal morbidity and mortality, respectively, it is important to understand the mechanism by which these medications may contribute to fetal acidosis. It is well known that reduced uteroplacental blood flow can result in impaired fetal oxygenation and fetal acidosis. This can occur indirectly via compression of vessels due to myometrial contractions or directly by vasoactive effects on umbilical vessels. So far, no studies have directly explored the role of the aforementioned vasopressors on myometrial contractions and umbilical vessel vasoconstriction. An in-vitro approach in isolated tissues will eliminate many clinical confounding variables, allowing direct comparison of the drugs in a controlled environment, and providing insight into the contractile mechanisms responsible for their neonatal effects. There is currently no consensus as to which vasopressor is best for the management of hypotension in obstetric patients and the mitigation of fetal acidosis. A survey of the members of the Society of Obstetric Anesthesia and Perinatology suggested significant variation in the practice of vasopressor use during cesarean deliveries. The evidence from animal studies contradicts the effects seen in human studies. This is possibly related to species differences in adrenergic receptor distribution, affinity to vasopressors, or placental transfer of vasopressors. It is well known that reduced uteroplacental blood flow can result in impaired fetal oxygenation and fetal acidosis. This can occur indirectly via compression of vessels due to myometrial contractions or directly by vasoactive effects on umbilical arteries. However, none of the studies so far have directly explored the role of the aforementioned vasopressors on myometrial contractions and umbilical artery vasoconstriction. An in-vitro approach in isolated tissues will eliminate many clinical confounding variables, allowing direct comparison of the drugs in a controlled environment, and providing insight into the contractile mechanisms responsible for their neonatal effects.

注册库
clinicaltrials.gov
开始日期
2019年7月8日
结束日期
2026年12月1日
最后更新
26天前
研究类型
Interventional
研究设计
Parallel
性别
Female

研究者

发起方
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
责任方
Sponsor

入排标准

入选标准

  • Patients who give written consent to participate in this study
  • Patients with gestational age 37-41 weeks
  • Patients of 19-40 years
  • Non-laboring patients, not exposed to exogenous oxytocin
  • Patients requiring elective primary or first repeat caesarean delivery
  • Patients undergoing caesarean delivery under spinal anesthesia

排除标准

  • Patients who refuse to give written informed consent
  • Patients who require general anesthesia
  • Patients in labor and those receiving oxytocin for induction of labor
  • Emergency caesarean delivery in labor
  • Patients who have had previous uterine surgery or \>1 previous caesarean delivery
  • Patients with any condition predisposing to uterine atony
  • Patients on medications that could affect myometrial contractility, such as insulin, nifedipine, labetolol or magnesium sulfate.

研究组 & 干预措施

Myometrium + Phenylephrine

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

干预措施: Phenylephrine

Myometrium + Ephedrine

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

干预措施: Ephedrine

Myometrium + Norepinephrine

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

干预措施: Norepinephrine

Umbilical artery + Ephedrine

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

干预措施: Ephedrine

Myometrium + Vasopressin

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

干预措施: Vasopressin

Umbilical artery + Phenylephrine

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

干预措施: Phenylephrine

Umbilical artery + Norepinephrine

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

干预措施: Norepinephrine

Umbilical artery + Vasopressin

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

干预措施: Vasopressin

Umbilical vein + Ephedrine

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

干预措施: Ephedrine

Umbilical vein + Phenylephrine

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

干预措施: Phenylephrine

Umbilical vein + Vasopressin

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

干预措施: Vasopressin

Umbilical vein + Norepinephrine

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

干预措施: Norepinephrine

结局指标

主要结局

Motility index

时间窗: 4 hours

Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

次要结局

  • Amplitude of contraction(4 hours)
  • Frequency of contraction(4 hours)
  • Integrated area under response curve (AUC)(4 hours)

研究点 (1)

Loading locations...

相似试验